Physician profile
Nancy Navarro
NPI 1265906523
$40,886.20
in general payments reported to CMS, 2019-2025
56 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,608 · 2022: $6,770 · 2023: $6,928 · 2024: $11K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,154 · Consulting Fee: $150 · Education: $9.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,193.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,154.45 |
| Consulting Fee | $150.00 |
| Education | $9.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,646.23 | 2021-2025 | |
| Biogen, INC. | $4,359.29 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $1,684.47 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,426.67 | 2021-2024 | Qelbree |
| Sk Life Science, INC. | $1,334.42 | 2021-2025 | Xcopri |
| Celgene Corporation | $1,307.22 | 2021-2025 | Zeposia |
| Ucb, INC. | $1,276.60 | 2021-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Pfizer INC. | $1,066.57 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,018.83 | 2021-2024 | Spravato |
| Mdd US Operations, LLC | $952.14 | 2022-2025 | Apokyn, Gocovri, Gocovri |
| Eisai INC. | $812.66 | 2022-2025 | |
| Amgen INC. | $784.15 | 2021-2025 | Uplizna |
| Horizon Therapeutics Plc | $681.26 | 2021-2023 | Uplizna |
| Genentech USA, INC. | $679.47 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $633.82 | 2021-2025 | Amyvid, Emgality, Kisunla |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $630.91 | 2023-2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $613.50 | 2024-2025 | Ponvory |
| Sunovion Pharmaceuticals INC. | $607.94 | 2021-2022 | |
| Genzyme Corporation | $589.35 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $574.18 | 2021-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $467.20 | 2021-2025 | Austedo Xr, Austedo |
| Electromed, INC. | $400.30 | 2021-2025 | Smartvest |
| Acadia Pharmaceuticals INC | $392.72 | 2021-2024 | Nuplazid, Daybue |
| Biohaven Pharmaceutical Holding Company LTD. | $347.01 | 2022 | |
| Sumitomo Pharma America, INC. | $339.28 | 2023-2024 | Aptiom |
| Axsome Therapeutics, INC. | $331.89 | 2025 | Symbravo |
| Avion Pharmaceuticals | $255.54 | 2022-2023 | Dhivy |
| Jazz Pharmaceuticals INC. | $241.39 | 2021-2025 | |
| Upsher-Smith Laboratories LLC | $238.90 | 2021-2023 | |
| Emd Serono, INC. | $218.17 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $211.57 | 2021-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Biohaven Pharmaceuticals, INC. | $187.36 | 2021 | |
| Neurelis, INC. | $177.21 | 2022-2025 | Valtoco |
| Argenx US, INC. | $172.74 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Currax Pharmaceuticals LLC | $164.35 | 2021-2023 | Onzetra Xsail |
| Sanofi-Aventis U.S. LLC | $149.99 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $115.72 | 2021 | |
| Novo Nordisk INC | $108.81 | 2022-2024 | Wegovy |
| Tg Therapeutics, INC. | $65.56 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.98 | 2024 | Hyqvia |
| Impel Pharmaceuticals INC. | $49.02 | 2023 | Trudhesa |
| Banner Life Sciences, LLC | $48.64 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $40.40 | 2023-2024 | Firdapse |
| Boston Scientific Corporation | $40.19 | 2023 | |
| Acorda Therapeutics, INC | $38.67 | 2024 | Ampyra, Inbrija |
| Livanova USA, INC. | $35.93 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $28.17 | 2022 | |
| Galderma Laboratories, L.P. | $27.52 | 2025 | |
| Genentech, INC. | $21.14 | 2023 | Enspryng |
| Adamas Pharmaceuticals, INC. | $19.40 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.45 | 2022 | |
| Ceribell, INC. | $17.17 | 2025 | Pocket Eeg Device |
| Itamar Medical INC | $16.89 | 2024 | Watchpatone |
| Xeris Pharmaceuticals, INC. | $15.78 | 2024 | Keveyis |
| Abbott Laboratories | $13.46 | 2023 | Infinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Navarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.